Results 201 to 210 of about 103,365 (348)

Dynamics of Apolipoprotein J Levels and Metabolic Parameters Following Bariatric Surgery

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Bariatric surgery has emerged as a potent intervention for ameliorating insulin resistance and its associated comorbidities in obese patients. Apolipoprotein J (ApoJ) and adiponectin are closely associated with insulin resistance and sensitivity, respectively.
Kellen Cristina da Cruz Rodrigues, Minjin Lee, Yejee Lim, Jennie Young, Brendon Chung, Susan Phillips, Theodore P. Ciaraldi, Young‐Bum Kim   +7 more
wiley   +1 more source

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +1 more source

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?

Journal of Diabetes, 2023
Zachary Bloomgarden
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols. [PDF]

Cureus
Davila Diaz R, Campos Barrera E, Diaz Fosado LA, Reyes Esparza A, Perez Benitez OA.   +4 more
europepmc   +1 more source

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice

, 2007
Desu Chen, Jiayu Liao, Na Li, Caihong Zhou, Qing Liu, Guangxing Wang, Rui Zhang, Song Zhang, Lilin Lin, Kaixian Chen, Xin Xie, Fajun Nan, Andrew A. Young, Ming‐Wei Wang   +13 more
openalex   +1 more source

Interactions of a Glucagon-like peptide 1 and a Glucagon-like peptide 1 analogue, liraglutide, with the endogenous receptor [PDF]

, 2015
Bukrinski, Jens T., Frederiksen, Tine Maja, Harris, Pernille, Peters, Günther H.J.   +3 more
core  

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source

Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensions

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Chronic stress, characterized by increased long‐term exposure to the glucocorticoid hormone cortisol, is increasingly linked to obesity development. Still, various knowledge gaps persist, including on underlying pathophysiological mechanisms. The aim of the current review is to provide the latest insights on the connection between stress and ...
Robin Lengton, Myrte Schoenmakers, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F. C. van Rossum   +4 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. [PDF]

PLoS Med
Chao AM, Gilden A, Wadden TA.
europepmc   +1 more source